Reminder: Changes in Hepatitis C Treatment Coverage for Medicaid Clients Begins Jan. 1

The Texas Health and Human Services Commission (HHSC) recently partnered with AbbVie to work toward significantly reducing chronic Hepatitis C in Medicaid patients. HHSC will publish an update to the Texas Medicaid Preferred Drug List (PDL) on Jan. 1 to designate preferred and non-preferred options for direct-acting antiviral (DAA) treatment.

Other news

• Younger Age Groups Now Eligible For Updated Bivalent COVID-19 Vaccines
• Annual Review of Clinical Prior Authorization Criteria Guides to Begin; Changes Scheduled for Feb. 7
• Androgenic Agents Clinical Prior Authorization Revisions Scheduled for Feb. 1, 2023
• Semi-annual Medicaid Preferred Drug List Update Coming Jan. 26